PubMed

Commentary on 'case series of liver failure associated with rosiglitazone and pioglitazone' by Floyd et al.

Osei SY, Koro CE, Cobitz AR, Kolatkar NS, Stender M.

Pharmacoepidemiol Drug Saf. 2009 Aug 4. [Epub ahead of print] No abstract available. PMID: 19655316 [PubMed - as supplied by publisher]Related articles

An assessment of the effect of thiazolidinedione exposure on the risk of myocardial infarction in type 2 diabetic patients.

Koro CE, Fu Q, Stender M.

Pharmacoepidemiol Drug Saf. 2008 Oct;17(10):989-96.PMID: 18759378 [PubMed - indexed for MEDLINE]Related articles

The incidence of heart failure among nondiabetic patients with and without impaired fasting glucose.

Nichols GA, Koro CE, Kolatkar NS.

J Diabetes Complications. 2009 May-Jun;23(3):224-8. Epub 2008 Apr 16.PMID: 18413158 [PubMed - indexed for MEDLINE]Related articles

The risk of myopathy associated with thiazolidinediones and statins in patients with type 2 diabetes: a nested case-control analysis.

Koro CE, Sowell MO, Stender M, Qizilbash N.

Clin Ther. 2008 Mar;30(3):535-42.PMID: 18405791 [PubMed - indexed for MEDLINE]Related articles

Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007.

Walker AM, Koro CE, Landon J.

Pharmacoepidemiol Drug Saf. 2008 Aug;17(8):760-8.PMID: 18383443 [PubMed - indexed for MEDLINE]Related articles

Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients.

Nichols GA, Koro CE.

Clin Ther. 2007 Aug;29(8):1761-70.PMID: 17919557 [PubMed - indexed for MEDLINE]Related articles

The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy.

Johannes CB, Koro CE, Quinn SG, Cutone JA, Seeger JD.

Pharmacoepidemiol Drug Saf. 2007 May;16(5):504-12.PMID: 17245800 [PubMed - indexed for MEDLINE]Related articles

Ethnic disparities and trends in glycemic control among adults with type 2 diabetes in the U.S. from 1988 to 2002.

Fan T, Koro CE, Fedder DO, Bowlin SJ.

Diabetes Care. 2006 Aug;29(8):1924-5. No abstract available. PMID: 16873805 [PubMed - indexed for MEDLINE]Related articlesFree article

The association between fibrate use, change in high-density lipoprotein cholesterol, and the risk of cardiovascular disease: a retrospective chart review involving up to 8 years of follow-up.

Nichols GA, Koro CE, Chan W, Bowlin SJ, Sprecher DL.

Clin Ther. 2006 Feb;28(2):243-50.PMID: 16678645 [PubMed - indexed for MEDLINE]Related articles

The independent correlation between high-density lipoprotein cholesterol and subsequent major adverse coronary events.

Koro CE, Bowlin SJ, Stump TE, Sprecher DL, Tierney WM.

Am Heart J. 2006 Mar;151(3):755.e1-755.e6.PMID: 16504648 [PubMed - indexed for MEDLINE]Related articles

The metabolic syndrome and schizophrenia: a review.

Meyer J, Koro CE, L'Italien GJ.

Int Rev Psychiatry. 2005 Jun;17(3):173-80. Review.PMID: 16194788 [PubMed - indexed for MEDLINE]Related articles

Atypical antipsychotic therapy and hyperlipidemia: a review.

Koro CE, Meyer JM.

Essent Psychopharmacol. 2005;6(3):148-57. Review.PMID: 15869022 [PubMed - indexed for MEDLINE]Related articles

Antidiabetic therapy and the risk of heart failure in type 2 diabetic patients: an independent effect or confounding by indication.

Koro CE, Bowlin SJ, Weiss SR.

Pharmacoepidemiol Drug Saf. 2005 Oct;14(10):697-703.PMID: 15654719 [PubMed - indexed for MEDLINE]Related articles

Major CHD risk factors predominate among African-American women who are eligible for lipid-lowering drug therapy under the new ATP III guidelines.

Koro CE, L'italien GJ, Fedder DO.

Eur J Cardiovasc Prev Rehabil. 2004 Oct;11(5):376-81.PMID: 15616409 [PubMed - indexed for MEDLINE]Related articles

The incidence of congestive heart failure associated with antidiabetic therapies.

Nichols GA, Koro CE, Gullion CM, Ephross SA, Brown JB.

Diabetes Metab Res Rev. 2005 Jan-Feb;21(1):51-7.PMID: 15386819 [PubMed - indexed for MEDLINE]Related articles

The incidence of congestive heart failure in type 2 diabetes: an update.

Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB.

Diabetes Care. 2004 Aug;27(8):1879-84.PMID: 15277411 [PubMed - indexed for MEDLINE]Related articlesFree article

The effects of antipsychotic therapy on serum lipids: a comprehensive review.

Meyer JM, Koro CE.

Schizophr Res. 2004 Sep 1;70(1):1-17. Review.PMID: 15246458 [PubMed - indexed for MEDLINE]Related articles

Thiazolidinedione-associated congestive heart failure and pulmonary edema.

Bowlin SJ, Koro CE.

Mayo Clin Proc. 2004 Apr;79(4):572, 575; author reply 575-7. Review. No abstract available. PMID: 15065628 [PubMed - indexed for MEDLINE]Related articlesFree article

Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report.

Koro CE, Bowlin SJ, Bourgeois N, Fedder DO.

Diabetes Care. 2004 Jan;27(1):17-20.PMID: 14693960 [PubMed - indexed for MEDLINE]Related articlesFree article

An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients.

Koro CE, Fedder DO, L'Italien GJ, Weiss S, Magder LS, Kreyenbuhl J, Revicki D, Buchanan RW.

Arch Gen Psychiatry. 2002 Nov;59(11):1021-6.PMID: 12418935 [PubMed - indexed for MEDLINE]Related articlesFree article

Primary prevention lipid-lowering drug therapy.

Fedder DO, Koro CE, L'Italien GJ.

Circulation. 2002 Aug 13;106(7):e35-6; author reply e35-6. No abstract available. PMID: 12176971 [PubMed - indexed for MEDLINE]Related articlesFree article

Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study.

Koro CE, Fedder DO, L'Italien GJ, Weiss SS, Magder LS, Kreyenbuhl J, Revicki DA, Buchanan RW.

BMJ. 2002 Aug 3;325(7358):243.PMID: 12153919 [PubMed - indexed for MEDLINE]Related articlesFree article

New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy: projected impact on the size, sex, and age distribution of the treatment-eligible population.

Fedder DO, Koro CE, L'Italien GJ.

Circulation. 2002 Jan 15;105(2):152-6.PMID: 11790693 [PubMed - indexed for MEDLINE]Related articlesFree article